Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years
Novartis AG (NYSE:NVS) released new data Wednesday from the ALITHIOS open-label extension study. Data show first-line ...
pharmaphorum22d
FDA extends review of Novartis' MS drug ofatumumab
The FDA has extended its review of Novartis’ potential multiple sclerosis drug ofatumumab, pushing back a decision on the repurposed cancer drug until September this year. Ofatumumab could ...
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the ...
pharmaphorum28d
Novartis drug effective in advanced MS
A Novartis drug has been shown to reduce risk of disability progression in secondary progressive multiple sclerosis, an advanced form of the disease. The Swiss pharma said the phase 3 EXPAND study ...
Novartis Breast Cancer Drug Helped Delay Return of Disease
Novartis AG’s breast cancer drug helped prevent the disease coming back a year after treatment had ended, in new data that ...
Investopedia6d
Novartis Breast Cancer Drug Found To Cut Disease Recurrence
Milan Jaros / Bloomberg via Getty Images Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease. The drug maker reported Kisqali along ...
STAT9d
FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug
Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...
FiercePharma9d
Roche doubles down with another subcutaneous FDA nod, this one for MS star Ocrevus
When Roche's Genentech gained approval for Ocrevus in 2017, the first-in- | On the same day that Roche gained an FDA approval ...
healthday on MSN4d
FDA Expands Use of Breast Cancer Drug Kisqali
Women with early stage breast cancer may now take Kisquali, a medication already approved for advanced disease, fo ...
FiercePharma25d
Novartis taps Lindy to turn biologic drugs into at-home injectables, puts nearly $1B on the line
The same device technology is also used in Novartis’ fast-growing multiple sclerosis drug Kesimpta. Pharma companies have been keen on developing subcutaneous injectables for IV medicines.
Yahoo Finance6d
Novartis Breast Cancer Drug Found To Cut Disease Recurrence
Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease. The drug maker reported Kisqali along with endocrine therapy (ET) reduced the risk ...